COMMUNIQUÉS West-GlobeNewswire

AMN Healthcare Announces Third Quarter 2025 Results
06/11/2025
Quarterly revenue of $634 million and adjusted EBITDA of $58 million ; GAAP income of $0.76 /share and adjusted EPS of $0.39 DALLAS, Nov. 06, 2025 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE: AMN), the [...]
Globus Medical Reports Third Quarter 2025 Results
06/11/2025
AUDUBON, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended September 30, 2025. Worldwide [...]
Mesa Labs Announces Second Quarter Results
06/11/2025
LAKEWOOD, Colo., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa” or “the Company”), a global leader in the design and manufacture of life science tools and critical quality control [...]
SRx Health Solutions Provides Response Related to Unusual Market Trading Activity Received by the NYSE American Exchange
06/11/2025
TAMPA, Fla., Nov. 06, 2025 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) (the “Company”) today announced the Company has been notified by the NYSE American of unusual trading activity of its [...]
Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update
06/11/2025
– CHS-114, a highly selective Treg depleter, clinical program expanded to include colorectal cancer – – Q3 2025 ending cash, cash equivalents and marketable securities of $191.7 million – – LOQTORZI ® net revenue was $ [...]
Omada Health Announces GLP-1 Prescribing Capability to Support Growing Member Population
06/11/2025
New capability to provide tailored and coordinated care informed by behavioral insights SAN FRANCISCO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual-first, between-visit health care provider [...]
Omada Health Reports Third Quarter 2025 Results
06/11/2025
Revenue of $ 68 million, up 49% ; 53% Member Growth Significant Reduction in Net Loss and First Quarter of Positive Adjusted EBITDA Announces New GLP-1 Prescribing Offering SAN FRANCISCO, Nov. 06, 2025 (GLOBE NEWSWIRE [...]
Nephros Announces Strong Third Quarter Financial Results; Achieving Highest Level of Programmatic Sales in Company History
06/11/2025
Third-Quarter Net Revenue of $4.8 million; Robust Growth Drives 35% Increase in Net Revenue and Fourth Consecutive Quarter of Profitability SOUTH ORANGE, NJ., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Nephros, Inc. (Nasdaq: [...]
CytomX Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update
06/11/2025
- CX-2051 Phase 1 data update on track for Q1 2026 - - CX-2051 Phase 1b CRC combination study with bevacizumab to start in Q1 2026 - - Positive CX-801 Phase 1 monotherapy biomarker data at SITC 2025 supportive of [...]
Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
06/11/2025
Announced expanded and accelerated Phase 3 Plan for CD388, its non-vaccine influenza preventative therapeutic Enrolled and dosed first patients in Phase 3 ANCHOR study; target enrollment on track for completion in the [...]
Progyny, Inc. Announces Third Quarter 2025 Results
06/11/2025
Reports Revenue of $313.3 Million, Reflecting 9.3% Growth Raises Full Year Guidance to Reflect Continued Strength in Member Engagement Selling Season Yields Over 80 New Clients, 900,000 New Lives, and Near 100% [...]
Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
06/11/2025
Topline 36-week data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for readouts by year-end 2025 Oral small molecule amylin receptor agonist (ACCG-2671) Phase 1 study [...]
Biofrontera Inc. to Report Third Quarter 2025 Financial Results on November 12, 2025 and Host a Conference Call on November 13, 2025
06/11/2025
WOBURN, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company") , a biopharmaceutical company specializing in the commercialization of dermatological products, announces [...]
Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
06/11/2025
First-in-human data from Phase 1 trial of MZE782 support best- and first-in-class potential; two Phase 2 proof-of-concept trials in phenylketonuria (PKU) and chronic kidney disease (CKD) expected to initiate in 2026 [...]
SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2025
06/11/2025
Corporate Update Conference Call Today at 4:30 PM ET NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today reported financial results [...]
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
06/11/2025
CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in [...]
Teknova Reports Third Quarter 2025 Financial Results
06/11/2025
Third quarter 2025 total revenue was $10.5 million, up 9% from prior year Achieves five consecutive quarters of year-over-year revenue growth Company reaffirms 2025 revenue guidance of $39-42 million HOLLISTER, Calif., [...]
Carlsmed Reports Third Quarter 2025 Financial Results and Raises Full-Year Guidance
06/11/2025
Third quarter revenue of $13.1 million, representing 98% growth YoY Raising full year 2025 revenue guidance to $49 million - $50 million CARLSBAD, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL [...]
Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights
06/11/2025
Tividenofusp alfa BLA review process for accelerated approval for MPS II continues with productive engagement with the FDA; commercial launch preparations on track DNL126 Phase 1/2 study enrollment completed, supporting [...]

Pages